| |
| |
|
| Insider
Information: |
Column Group Ii Gp, Lp |
| Relationship: |
10% Owner |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
800,000 |
|
|
Indirect Shares
|
1,000 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$1,540 |
|
|
| Total
Shares |
801,000 |
|
|
| Total
Value |
$1,540 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
59
|
0
|
|
Stock
price went up :
|
24
|
0
|
| Stock
price went down : |
35
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -3.1%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
800,000 |
|
0 |
Premium* |
|
|
Ngm Biopharmaceuticals Inc |
NGM |
10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
78 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-03-31 |
4 |
B |
$12.53 |
$1,479,380 |
D/D |
118,067 |
1,156,237 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-04-01 |
4 |
B |
$12.26 |
$1,447,501 |
D/D |
118,067 |
1,274,304 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-04-02 |
4 |
B |
$12.40 |
$184,140 |
D/D |
14,850 |
1,289,154 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-04-03 |
4 |
B |
$12.41 |
$181,025 |
D/D |
14,587 |
1,303,741 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-04-07 |
4 |
B |
$14.38 |
$1,779,209 |
D/D |
123,728 |
1,427,469 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-04-08 |
4 |
B |
$14.95 |
$1,683,400 |
D/D |
112,602 |
1,540,071 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-24 |
4 |
B |
$17.93 |
$1,232,670 |
D/D |
68,749 |
1,609,013 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-27 |
4 |
B |
$17.99 |
$68,974 |
D/D |
3,834 |
1,612,847 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-28 |
4 |
B |
$17.99 |
$73,849 |
D/D |
4,105 |
1,616,952 |
2.45 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-30 |
4 |
B |
$17.99 |
$13,169 |
D/D |
732 |
1,617,684 |
2.37 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-17 |
4 |
B |
$13.42 |
$1,194,779 |
I/I |
89,049 |
45,610 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-18 |
4 |
B |
$13.20 |
$827,224 |
I/I |
62,650 |
47,677 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-24 |
4 |
B |
$13.37 |
$238,325 |
I/I |
17,828 |
49,575 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-25 |
4 |
B |
$13.43 |
$581,624 |
I/I |
43,292 |
51,004 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-26 |
4 |
B |
$13.49 |
$272,582 |
I/I |
20,201 |
51,671 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-27 |
4 |
B |
$13.45 |
$36,453 |
I/I |
2,710 |
51,760 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-31 |
4 |
B |
$13.47 |
$832,267 |
I/I |
61,806 |
53,800 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-06-01 |
4 |
B |
$13.45 |
$1,237,400 |
I/I |
92,000 |
56,836 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-06-09 |
4 |
B |
$13.50 |
$13,286,174 |
I/I |
984,161 |
90,442 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-10-27 |
4 |
B |
$4.86 |
$373,638 |
I/I |
76,877 |
200,697 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-11-03 |
4 |
B |
$4.99 |
$519,107 |
I/I |
104,090 |
304,787 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-11-04 |
4 |
B |
$4.72 |
$165,320 |
I/I |
35,058 |
339,845 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-11-21 |
4 |
B |
$5.00 |
$179,942 |
I/I |
35,997 |
375,842 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-11-22 |
4 |
B |
$5.00 |
$21,646 |
I/I |
4,330 |
380,172 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-12-12 |
4 |
B |
$4.98 |
$1,493 |
I/I |
300 |
380,472 |
1.42 |
% |
|
78 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
